Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Buying activity fuels Indian indices
Wed, 10 Jun Closing

Despite negative international cues, the Indian stock markets gained momentum throughout the day led by buying activity across index heavyweights. While the BSE-Sensex closed higher by around 359 points, the NSE-Nifty closed higher by around 103 points. The S&P BSE Midcap and the S&P BSE Smallcap also did well to notch gains of 1% each. Gains were largely seen in auto, IT and capital goods stocks.

As regards to major global markets, European shares dropped for a seventh straight session to trade near a 3-1/2 month low. Asian markets finished broadly lower today with shares in Hong Kong bearing majority of the brunt. The Hang Seng is down 1.09%, while Japan's Nikkei 225 is off 0.25% and China's Shanghai Composite is lower by 0.15%. The rupee was trading strong at RS 63.88 against the American dollar in the afternoon session.

According to a leading financial daily, Sun Pharmaceutical Industries has marked its entry into the branded Ophthalmology segment in the US. Sun Pharma Advanced Research Company (SPARC) has licensed out Xelpros (Latanoprost BAK-free eye drops) to a subsidiary of Sun Pharmaceutical Industries for the US market. This is a part of Sun Pharma’s strategy to strengthen its presence in the US specialty segment. In addition to the up-front payment of US$ 3 m, SPARC will receive certain other milestone payments, both totaling to US$ 16 m from Sun Pharma. It is also eligible for certain defined royalties and additional milestone payments linked to the actual sales performance of Xelpros. In December 2014, the USFDA had issued a Complete Response letter to SPARC for its New Drug Application (NDA) for Latanoprost BAK-free eye drops.

Shares of Punjab National Bank (PNB) surged over 1.2% after it was reported that the company has inked a Memorandum of Understanding (MoU) with the Indian Army for Defence Salary Package. The first MoU between PNB and the Indian Army was signed in 2011 and was valid for a period of three years. The MoU is custom made to suit the requirements of serving soldiers, pensioners and families. Besides, number of additional facilities have been incorporated in the revised MoU after due consultation between Bank & Army authorities. Some features which have been improved from the previous MoU are that the Personal Accidental Insurance cover has been extended to Rs 200,000 and Rs 500,000 from Rs 50,000 and Rs 200,000 respectively.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Buying activity fuels Indian indices". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.